CD274 / PD-L1 / B7-H1, N-His, recombinant protein from ProteoGenix; catalogue PX-P5608; research use only.
Know who made it. See the evidence. Buy through one marketplace.
CD274 / PD-L1 / B7-H1 is a type I transmembrane protein that is expressed on the surface of various cells, including antigen-presenting cells. It is composed of a single extracellular immunoglobulin-like domain, a transmembrane domain, and a short cytoplasmic tail.
ActivityCD274 / PD-L1 / B7-H1 is an inhibitory receptor that binds to its ligand, programmed cell death-1 (PD-1), expressed on the surface of activated T cells. This interaction suppresses T cell activation and proliferation, and promotes the induction of tolerance.
ApplicationCD274 / PD-L1 / B7-H1 is involved in the regulation of immune responses and is a target for immunotherapy. The use of monoclonal antibodies to block the interaction between CD274 / PD-L1 / B7-H1 and PD-1 has been shown to enhance anti-tumor immunity, leading to improved clinical outcomes in cancer patients.
ProteoGenix catalogue number PX-P5608. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Purity: >90% as determined by SDS-PAGE; Molecular weight: 27.50 kDa; Tag: N-terminal His Tag; Fragment: Phe19-Arg238; Buffer: PBS, pH7.5; Applications: ELISA, WB.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
